Full Breakdown
Supreme Court Blocks Trump Administration’s Transgender Inmate Care Restrictions
By Drooid · · How we work
Supreme Court Decision (October 21)
The United States Supreme Court issued an unsigned, one-sentence order refusing to lift a district-court injunction that bars the Federal Bureau of Prisons (BOP) from enforcing a new policy that would end gender-affirming medical care for transgender inmates. The order contains no explanation of the Court’s reasoning. Conservative Justices Clarence Thomas and Samuel Alito indicated they would have granted the administration’s emergency request.
Background & Context
In response, the BOP adopted a policy in February that would prohibit surgeries, hormone treatments, and “social accommodations” such as wigs, makeup, and gender-aligned clothing, while preserving access to mental-health services. The federal prison system has provided hormone therapy to inmates with gender dysphoria since at least 1992.
Data & Statistics
- The government’s 2025 figure places more than 2,000 transgender individuals in federal prisons and halfway houses.
- Plaintiffs and advocacy groups cite about 1,000 transgender inmates as being at risk of losing treatment.
- BOP records show approximately 600 inmates were receiving hormone therapy in 2025.
These differing counts illustrate uncertainty about the exact population affected.
Official Statements & Responses
Criticism & Opposition
The American Civil Liberties Union contended that the policy would cause “immediate and catastrophic” harm, noting that abrupt cessation of hormone therapy can lead to increased depression, anxiety, suicidal ideation, and self-harm. ACLU lawyers emphasized that the BOP provided no evidence linking gender-affirming treatment to security incidents over three decades.
Conflicting Reports & Gaps
- Inmate population: Sources differ between “about 1,000” at risk and “more than 2,000” housed in federal facilities. Both figures are presented without reconciliation.
- Security justification: The administration claims the policy addresses security concerns, yet the BOP has not documented any specific incident linking hormone therapy to safety risks.
- Evidence of medical necessity: Plaintiffs point to longstanding medical practice since 1992, while the government labels the treatments “unproven sex-rejecting interventions” without providing supporting studies.
Verbatim Quotes
- “This ruling will prevent serious and irreparable harm to plaintiffs and the class while we continue to challenge the government's unlawful efforts to deny medically necessary healthcare for political reasons,” — Aditi Shah, an attorney at the American Civil Liberties Union
- “With this opinion, the court has no intention of wading into the culture war being waged against transgender individuals," Lamberth wrote.” — Royce Lamberth, district judge
- “In nullifying BOP’s exercise of its statutorily conferred authority to adopt a policy that prison administrators have determined is necessary to maintain institutional security, the court’s order causes irreparable harm to the government and to the public,” — General D. John Sauer
What’s Next
The district-court injunction remains in force while the class-action lawsuit proceeds. The appeals court’s September 18 decision refusing to stay the injunction indicates that the litigation will continue in lower courts, leaving the ultimate legality of the BOP policy unresolved.